BMS Moves Closer To Subcutaneous Opdivo With Phase III Trial Success

 
• By Joseph Haas
  
Chemical process
Bristol makes progress in formulating a subcutaneous version of Opdivo • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer